Inventor · disambiguated record
Katja Jantos
Also filed as: JANTOS KATJA
23 granted patents·17 pending applications·29 citations·filing 2010–2024
91Inventor score
Top patents by PatentIndex Score
40 records- 0186US2025313572A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 0283US9938269B2Inhibitor compounds of phosphodiesterase type 10AGENESTE HERVE·Filed 2012·Granted Apr 10, 2018·7 cites·33 claims
- 0383US9527856B2Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseasesABBVIE DEUTSCHLAND·Filed 2015·Granted Dec 27, 2016·4 cites·38 claims
- 0482US2024228509A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2023·Application pending·0 cites
- 0581US8283363B2Carboxamide compounds and their use as calpain inhibitorsMACK HELMUT·Filed 2010·Granted Oct 9, 2012·5 cites·21 claims
- 0681US2025092062A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 0778US8664214B2Small molecule potentiators of metabotropic glutamate receptors IBRAJE WILFRIED·Filed 2011·Granted Mar 4, 2014·5 cites·19 claims
- 0878US2023399340A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 0977US2022259226A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 1075US9790203B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2013·Granted Oct 17, 2017·2 cites·26 claims
- 1175US9200005B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2014·Granted Dec 1, 2015·3 cites·23 claims
- 1275US2023183261A1Macrocyclic MCL-1 Inhibitors and Methods of UseABBVIE INC·Filed 2022·Application pending·0 cites
- 1371US8314120B2Small molecule potentiators of metabotropic glutamate receptorsBRAJE WILFRIED·Filed 2011·Granted Nov 20, 2012·2 cites·32 claims
- 1470US2021292339A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2020·Application pending·0 cites
- 1568US2020325153A1Macrocyclic MCL-1 Inhibitors and Methods of UseABBVIE INC·Filed 2020·Application pending·0 cites
- 1666US8598211B2Carboxamide compounds and their use as calpain inhibitors IVKLING ANDREAS·Filed 2010·Granted Dec 3, 2013·1 cites·13 claims
- 1765US2020255451A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2018·Application pending·0 cites
- 1865US2019055264A1Macrocyclic MCL-1 inhibitors and methods of useABBVIE INC·Filed 2018·Application pending·0 cites
- 1965US2020239494A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2018·Application pending·0 cites
- 2064US2020010480A1Macrocyclic MCL-1 Inhibitors and Methods of UseABBVIE INC·Filed 2019·Application pending·0 cites
- 2163US9527811B2Carboxamide compounds and their use as calpain inhibitorsABBVIE DEUTSCHLAND·Filed 2014·Granted Dec 27, 2016·0 cites·34 claims
- 2257US9018206B2Carboxamide compounds and their use as calpain inhibitorsMACK HELMUT·Filed 2012·Granted Apr 28, 2015·0 cites·35 claims
- 2354US9567325B2Carboxamide compounds and their use as calpain inhibitorsABBVIE DEUTSCHLAND·Filed 2014·Granted Feb 14, 2017·0 cites·32 claims
- 2451US9273036B2Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseasesABBVIE DEUTSCHLAND·Filed 2014·Granted Mar 1, 2016·0 cites·27 claims
- 2551US8236798B2Carboxamide compounds and their use as calpain inhibitorsMACK HELMUT·Filed 2010·Granted Aug 7, 2012·0 cites·15 claims
- 2651US2014179702A1Carboxamide compounds and their use as calpain inhibitors ivABBVIE INC·Filed 2013·Application pending·0 cites
- 2750US2018222905A1Novel inhibitor compounds of phosphodiesterase type 10aABBVIE DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 2849US9657034B2Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitorsABBVIE DEUTSCHLAND·Filed 2016·Granted May 23, 2017·0 cites·61 claims
- 2949US2016168135A1Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressin-related diseasesABBVIE DEUTSCHLAND·Filed 2016·Application pending·0 cites
- 3049US2018030033A1Novel inhibitor compounds of phosphodiesterase type 10aABBVIE INC·Filed 2017·Application pending·0 cites
- 3147US9862704B2Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseasesABBVIE DEUTSCHLAND·Filed 2014·Granted Jan 9, 2018·0 cites·30 claims
- 3246US9840495B2Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseasesABBVIE DEUTSCHLAND·Filed 2014·Granted Dec 12, 2017·0 cites·29 claims
- 3345US9051304B2Carboxamide compounds and their use as calpain inhibitors VKLING ANDREAS·Filed 2010·Granted Jun 9, 2015·0 cites·11 claims
- 3442US9657002B2Oxindole derivatives carrying an oxetane substituent and use thereof for treating vassopressin-related diseasesABBVIE DEUTSCHLAND·Filed 2014·Granted May 23, 2017·0 cites·28 claims
- 3542US9150545B2Carboxamide compounds and their use as calpain inhibitors VABBVIE DEUTSCHLAND·Filed 2013·Granted Oct 6, 2015·0 cites·22 claims
- 3642US8906941B2Carboxamide compounds and their use as calpain inhibitorsKLING ANDREAS·Filed 2010·Granted Dec 9, 2014·0 cites·26 claims
- 3741US2015252017A1Carboxamide compounds and their use as calpain inhibitors vABBVIE DEUTSCHLAND·Filed 2015·Application pending·0 cites
- 3838US9062027B2Carboxamide compounds and their use as calpain inhibitors VKLING ANDREAS·Filed 2011·Granted Jun 23, 2015·0 cites·7 claims
- 3936US9688678B2Oxindole compounds carrying a nitrogen-bound spiro substituent and use thereof for treating vasopressin-related diseasesABBVIE DEUTSCHLAND·Filed 2015·Granted Jun 27, 2017·0 cites·31 claims
- 4035US9617226B2Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseasesABBVIE DEUTSCHLAND·Filed 2015·Granted Apr 11, 2017·0 cites·29 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →